Renal Biopsy Safety and Indications

Introduction to Renal Biopsy

Renal biopsy is safe and strongly recommended in patients with impaired renal function when ultrasound shows no cortical atrophy or hyperechogenicity, as these findings indicate potentially reversible disease that requires histologic diagnosis to guide treatment, according to the American College of Physicians and the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2

The complication rate of renal biopsy is acceptably low, even in patients with impaired renal function, with major complications requiring intervention occurring in only 0.032-0.7% of cases, and death occurring in approximately 0.009-0.33% of cases, as reported by the American College of Radiology 3
Patients with chronic kidney disease do not have increased bleeding risk from biopsy compared to those without CKD, and the risk of complications in patients with diabetic kidney disease is no greater than in patients with other causes of chronic kidney disease, according to the National Kidney Foundation 3

Renal biopsy should be performed whenever feasible in patients with unexplained renal dysfunction, including those with significant proteinuria, evidence of progressive disease, unexplained acute or subacute renal failure, or acute nephritic syndrome, as recommended by the American Society of Nephrology 1
Clinical markers alone cannot predict histological diagnosis, and treatment options and prognosis are directly influenced by the actual histological findings, emphasizing the importance of biopsy in patients with impaired renal function, according to the European Renal Association 1
In patients with monoclonal gammopathy and renal dysfunction, kidney biopsy is essential for diagnosis of MGRS, as 45% of patients with suspected MGRS do not actually have an MGRS-associated disorder, as reported by the International Society of Nephrology 2

To minimize complications, specific precautions should be taken, including limiting needle passes to 4 or fewer, ensuring normal bleeding and partial thromboplastin times prior to the procedure, and ensuring patient cooperation during the procedure, as recommended by the American College of Radiology 3

Transjugular (transvenous) renal biopsy is available for patients with contraindications to percutaneous biopsy, such as bleeding disorders, severe coagulopathy, or inability to cooperate with the procedure, and should be considered in high-risk patients from whom it would otherwise be difficult to obtain kidney tissue, according to the Society of Interventional Radiology 2, 3

Do not withhold renal biopsy based solely on the presence of impaired renal function, as the absence of cortical atrophy or hyperechogenicity actually strengthens the indication for biopsy rather than weakening it, and ultrasound abnormalities like increased cortical echogenicity and loss of corticomedullary differentiation are late findings that occur well after the onset of dysfunction and indicate more advanced, potentially irreversible disease, as reported by the American College of Radiology 1, 4, 5